Advertisement

Correlates of Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes Mellitus (from the Department of Veterans Affairs)

      This study used data from the Veterans Affairs administrative and clinical dataset to evaluate determinants of glucagon-like peptide-1 receptor agonist (GLP-1 RA) use among patients with concomitant atherosclerotic cardiovascular disease and diabetes mellitus and an antecedent primary care provider visit. The prevalence of GLP-1 RA use was 8.0%. In multivariable-adjusted models, White race, hypertension, obesity, higher hemoglobin A1c, ischemic heart disease, chronic kidney disease, a higher number of primary care provider visits, and previous cardiology or endocrinology visits were directly associated with GLP-1 RA use. Older age, having a physician primary care provider, and receiving care at a teaching facility were inversely associated with GLP-1 RA use. Our data can help inform targeted interventions to promote equitable access to GLP-1 RA and incentivize the adoption of these disease-modifying agents in high-risk patient populations.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Virani SS
        • Alonso A
        • Aparicio HJ
        • Benjamin EJ
        • Bittencourt MS
        • Callaway CW
        • Carson AP
        • Chamberlain AM
        • Cheng S
        • Delling FN
        • Elkind MSV
        • Evenson KR
        • Ferguson JF
        • Gupta DK
        • Khan SS
        • Kissela BM
        • Knutson KL
        • Lee CD
        • Lewis TT
        • Liu J
        • Loop MS
        • Lutsey PL
        • Ma J
        • Mackey J
        • Martin SS
        • Matchar DB
        • Mussolino ME
        • Navaneethan SD
        • Perak AM
        • Roth GA
        • Samad Z
        • Satou GM
        • Schroeder EB
        • Shah SH
        • Shay CM
        • Stokes A
        • VanWagner LB
        • Wang N
        • Tsao CW
        • American Heart Association Council on Epidemiology and Prevention Statistics
        Committee and stroke statistics subcommittee heart disease and stroke statistics—2021 update: a report From the American Heart Association.
        Circulation. 2021; 143: e254-e743
        • Kristensen SL
        • Rørth R
        • Jhund PS
        • Docherty KF
        • Sattar N
        • Preiss D
        • Køber L
        • Petrie MC
        • McMurray JJV.
        Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
        Lancet Diabetes Endocrinol. 2019; 7 ([published correction appears in Lancet Diabetes Endocrinol 2020;8:e2]): 776-785
        • American Diabetes Association
        10. Cardiovascular disease and risk management: standards of medical care in diabetes—2019.
        Diabetes Care. 2018; 42: S103-S123
        • Draznin B
        • Aroda VR
        • Bakris G
        • Benson G
        • Brown FM
        • Freeman R
        • Green J
        • Huang E
        • Isaacs D
        • Kahan S
        • Leon J
        • Lyons SK
        • Peters AL
        • Prahalad P
        • Reusch JEB
        • Young-Hyman D
        • Das S
        • Kosiborod M.
        • American Diabetes Association Professional Practice Committee
        • American Diabetes Association Professional Practice Committee
        9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2022.
        Diabetes Care. 2021; 45: S125-S143
        • Eberly LA
        • Yang L
        • Essien UR
        • Eneanya ND
        • Julien HM
        • Luo J
        • Nathan AS
        • Khatana SAM
        • Dayoub EJ
        • Fanaroff AC
        • Giri J
        • Groeneveld PW
        • Adusumalli S.
        Racial, ethnic, and socioeconomic inequities in glucagon-like Peptide-1 receptor agonist use among patients with diabetes in the US.
        JAMA Health Forum. 2021; 2e214182
        • Arnold SV
        • de Lemos JA
        • Rosenson RS
        • Ballantyne CM
        • Liu Y
        • Mues KE
        • Alam S
        • Elliott-Davey M
        • Bhatt DL
        • Cannon CP
        • Kosiborod M
        • Investigators GOULD
        Use of guideline-recommended risk reduction strategies among patients with diabetes and atherosclerotic cardiovascular disease.
        Circulation. 2019; 140: 618-620
        • Al Rifai M
        • Mahtta D
        • Ramsey DJ
        • Lee MT
        • Krittanawong C
        • Navaneethan SD
        • Gregg LP
        • Petersen LA
        • Virani SS
        Correlates of SGLT-2-inhibitiors use among patients with atherosclerotic cardiovascular disease and type 2 diabetes mellitus: insights from the Department of Veterans Affairs.
        Am Heart J. 2021; (])https://doi.org/10.1016/j.ahj.2021.12.006
        • Gunawan F
        • Partridge C
        • Kosiborod M
        • Inzucchi S.
        SUN-149 Cardiologist vs. endocrinologist Encounters in Patients with T2D and CVD: potential Implications for Glucose-Lowering Therapy Use and Education.
        J Endocr Soc. 2019; 3: SUN-149
        • Nelson AJ
        • Pagidipati NJ
        • Aroda VR
        • Cavender MA
        • Green JB
        • Lopes RD
        • Al-Khalidi H
        • Gaynor T
        • Kaltenbach LA
        • Kirk JK
        • Lingvay I
        • Magwire ML
        • O'Brien EC
        • Pak J
        • Pop-Busui R
        • Richardson CR
        • Reed M
        • Senyucel C
        • Webb L
        • McGuire DK
        • Granger CB
        Incorporating SGLT2i and GLP-1RA for cardiovascular and kidney disease risk reduction: call for action to the Cardiology Community.
        Circulation. 2021; 144: 74-84
        • Navaneethan SD
        • Zoungas S
        • Caramori ML
        • Chan JCN
        • Heerspink HJL
        • Hurst C
        • Liew A
        • Michos ED
        • Olowu WA
        • Sadusky T
        • Tandon N
        • Tuttle KR
        • Wanner C
        • Wilkens KG
        • Lytvyn L
        • Craig JC
        • Tunnicliffe DJ
        • Howell M
        • Tonelli M
        • Cheung M
        • Earley A
        • Rossing P
        • Boer IH de
        • Khunti K.
        Diabetes management in chronic kidney disease: synopsis of the 2020 KDIGO clinical practice guideline.
        Ann Intern Med. 2021; 174: 385-394
        • Shah M
        • Vella A.
        Effects of GLP-1 on appetite and weight.
        Rev Endocr Metab Disord. 2014; 15: 181-187
      1. Mahtta D, Ramsey DJ, Lee MT, Chen L, Al Rifai M, Akeroyd JM, Vaughan EM, Matheny ME, Santo KRDE, Navaneethan SD, Lavie CJ, Birnbaum Y, Ballantyne CM, Petersen LA, Virani SS. Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs. Diabetes Care. 2022 Feb 1;45(2):372-380. doi: 10.2337/dc21-1815. PMID: 35015080.